Current evidence supports at most a Limited and possibly disputed association between pathogenic variation in SPRN and susceptibility to human prion diseases grouped under prion disease. The main human genetic study identified one rare frameshift allele and common polymorphisms nominally associated with variant and sporadic Creutzfeldt–Jakob disease in case–control analyses, but there is minimal replication, no clear segregation within families, and effect sizes are modest with p values close to conventional significance thresholds in a single cohort of 522 prion disease cases and 861 controls PMID:18805828. Experimental work in animal models and livestock shows that SPRN functions in prion biology and host response but does not yet provide a direct, mechanistically validated link between specific human SPRN variants and prion disease onset or course PMID:18805828, PMID:19917049, PMID:33713980, PMID:22723200. Overall, based on ClinGen-style criteria, the gene–disease association currently best fits a Limited category, with some elements that could be interpreted as Disputed until independent replication is available.
Prion diseases in humans (including sporadic and variant Creutzfeldt–Jakob disease) are typically considered neurodegenerative, rapidly fatal disorders, often presenting as adult-onset encephalopathy with cognitive decline, ataxia, and myoclonus. For SPRN, the evidence relates to disease susceptibility, not Mendelian causation, and no consistent mode of inheritance (autosomal dominant, recessive, or X‑linked) has been established. In the largest available human study, sequencing of the SPRN open reading frame and adjacent regions in 522 prion disease patients (107 variant CJD, remaining predominantly sporadic CJD) and 861 controls identified a coding frameshift variant, common coding and intronic single-nucleotide polymorphisms (SNPs), and additional rare indels PMID:18805828. No familial segregation data were reported, and cases were largely unrelated.
The key variant highlighted is a single base-pair insertion at codon 46, described at the transcript level as c.139dup (p.Ser47PhefsTer?) in the variant table, predicted to introduce a frameshift and generate a truncated or altered protein PMID:18805828. This allele was observed in 2 patients with variant CJD and in 0 of 861 controls, yielding a nominal p value of 0.01 for association PMID:18805828. Given the very small number of carriers and lack of replication, the corresponding odds ratio is imprecise and not sufficient for strong causal inference. Two additional linked SNPs (one intronic and one missense at codon 7) were associated with sporadic CJD risk (p = 0.009) PMID:18805828. These polymorphisms likely represent low‑penetrance susceptibility alleles rather than deterministic pathogenic variants.
Beyond this single human cohort, the available genetic data are indirect. In Polish cattle with atypical bovine spongiform encephalopathy (BSE), sequencing of the bovine SPRN open reading frame identified a rare coding variation in one L‑type atypical BSE case, but no systematic difference in SPRN coding variants between 6 BSE cases and healthy Holstein controls was reported, and no clearly pathogenic alleles were defined PMID:22723200. These data suggest that while SPRN variation occurs in prion‑affected animals, its role as a major susceptibility locus is not firmly established.
No human study has reported segregation of SPRN variants within multiplex families with prion disease, and there are no reports of de novo pathogenic variants with strong genotype–phenotype correlation. Moreover, no penetrance estimates, allele frequencies, or population‑based risk metrics (beyond case–control p values) are provided for the human variants, and the study design does not exclude confounding or population stratification PMID:18805828. The overall variant spectrum in humans appears to consist of a rare frameshift allele (c.139dup (p.Ser47PhefsTer?)), a small number of rare insertion/deletion variants (not individually specified in the abstract), and several common SNPs, including at least one missense substitution at codon 7 PMID:18805828. Founder effects, deep‑intronic variants, and structural rearrangements have not been described.
SPRN (Shadoo) encodes a glycosylphosphatidylinositol-anchored glycoprotein with structural similarity to the prion protein (PrP). Experimental work indicates biological interactions and partial functional redundancy between Shadoo and PrP. In livestock, analysis of the ovine SPRN gene identified 26 mutations across promoter, intronic, coding, and 3′ untranslated regions; a deletion of two alanine residues in the coding sequence was associated with susceptibility to classical scrapie, and multiple promoter variants altered gene expression in vitro, highlighting SPRN’s biological relevance to prion pathogenesis PMID:19917049. However, these findings derive from sheep and scrapie and cannot be directly generalized to human prion disease without further corroboration.
Mouse models have further clarified the physiological role of SPRN, although not specifically in prion disease onset. Double knockout of Prnp and Sprn in FVB/N mice results in intra‑uterine growth retardation, suspected placental dysfunction, increased perinatal lethality, and defects in lactation PMID:33713980. Transcriptomic analyses of placental tissue in these double‑knockout animals reveal alterations in developmental pathways and support a complex interaction between PrP and Shadoo PMID:33713980. While these data confirm that SPRN is biologically active and intersects with PrP‑related pathways, they do not directly demonstrate that specific human SPRN alleles cause or modify prion neurodegeneration.
In vitro functional analyses of ovine SPRN promoter variants demonstrate that mutations between −464 and −230 bp upstream of exon 1, encompassing putative AP‑2 and Sp1 binding sites, significantly modulate promoter activity PMID:19917049. Six promoter variants altered expression in reporter assays, supporting a model in which SPRN expression level could influence susceptibility to prion infection or propagation PMID:19917049. The human study PMID:18805828 did not, however, provide functional characterization of its identified variants (including c.139dup (p.Ser47PhefsTer?)), nor did it show how these variants affect Shadoo expression, localization, or interaction with PrP.
Several aspects temper the strength of the proposed SPRN–prion disease association. First, association signals are modest and based on a single human case–control study, with no published replication in independent cohorts PMID:18805828. The nominal p values (p = 0.01 and p = 0.009) could be vulnerable to multiple‑testing effects, particularly given the number of variants screened. Second, the absence of familial segregation data or strong effect sizes makes it difficult to distinguish true biological susceptibility factors from statistical noise or linkage disequilibrium with other loci, such as PRNP. Third, cattle data in atypical BSE do not show a consistent pattern of pathogenic SPRN variants in affected animals versus controls, limiting the cross‑species support for a primary susceptibility role PMID:22723200. Finally, mouse double‑knockout models show important developmental and reproductive phenotypes but have not been reported to spontaneously develop prion disease in the absence of exogenous infection, suggesting that SPRN is not a sole determinant of prion neurodegeneration PMID:33713980.
Taken together, the current data indicate that SPRN is biologically connected to prion pathways and may modulate susceptibility to prion diseases, but the human genetic evidence is limited to one case–control study with modest associations, very few carriers of a single rare frameshift variant, and no supportive family‑based or functional validation specific to the human alleles PMID:18805828. Animal and livestock studies support a role for SPRN in prion biology and host response PMID:19917049, PMID:33713980, PMID:22723200, but they do not yet fulfill criteria for a strong or definitive human gene–disease relationship. There is no evidence that SPRN variants alone are sufficient to cause prion disease, and the effect, if present, is likely that of a low‑penetrance risk modifier rather than a Mendelian determinant.
From a diagnostic standpoint, routine clinical testing of SPRN for prion disease is not currently justified, and any variants identified incidentally should be interpreted with caution and generally not used for predictive counseling in the absence of robust replication. For research or commercial genotyping panels aimed at prion disease susceptibility, inclusion of SPRN variants (particularly c.139dup (p.Ser47PhefsTer?) and the codon 7 missense SNP) may be of exploratory interest, but results should be clearly labeled as non‑diagnostic, low‑evidence risk markers. Additional large, multi‑ethnic studies with rigorous replication, functional assays of specific human variants, and integrative analyses with PRNP genotype will be required to refine the clinical relevance of SPRN.
Key take‑home sentence: Current evidence supports SPRN as a biologically plausible but only weakly supported susceptibility gene for prion disease, and SPRN testing should not be used in isolation for clinical decision‑making at this time.
Gene–Disease AssociationLimitedSingle human case–control cohort with nominally significant associations (including 2 variant CJD probands carrying a rare frameshift and common SNPs associated with sporadic CJD) but no family segregation, no replication, and only indirect animal data. Genetic EvidenceLimitedHuman evidence consists of 522 prion disease cases and 861 controls with one rare frameshift variant observed in 2 vCJD cases and 0 controls and two common SNPs associated with sporadic CJD; no segregation or de novo data and uncertain effect sizes. Functional EvidenceModerateOvine and bovine data show SPRN polymorphisms affecting promoter activity and associations with scrapie or atypical BSE, and mouse Prnp/Sprn double knockouts demonstrate overlapping biological roles, but there is no direct functional validation of specific human SPRN variants in prion pathogenesis. |